Nkarta (NKTX) Other Operating Expenses (2019 - 2020)

Nkarta (NKTX) posted quarterly Other Operating Expenses of -$40.7 million for Q2 2020, down 7148.62% quarter-over-quarter from $578000.0 in Q1 2020.

Nkarta (NKTX) Other Operating Expenses (2019 - 2020) Analysis & Trends

Nkarta's Other Operating Expenses history runs 2 years deep, the most recent figure standing at -$40.7 million for Q2 2020.

In Q2 2020, Other Operating Expenses changed N/A year-over-year to -$40.7 million; the TTM figure through Mar 2021 stood at -$40.7 million (down 2248.79% YoY), while the FY2020 annual figure was -$40.2 million, down 3147.27% from the prior year.
Other Operating Expenses for Q2 2020 stood at -$40.7 million, down from $578000.0 in the prior quarter.
The five-year high for Other Operating Expenses was $3.4 million in Q3 2019, with the low at -$40.7 million in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Nkarta	201.14 Mn	201.14 Mn	-

Download Data